Видео с ютуба Cdk4

Adjuvant CDK4/6 Inhibition: When it Will Become Routine

SONIA: optimal CDK4/6 inhibitor position in HR+, HER2- advanced BC

Спросите эксперта: Стефани Графф ответит на ваши вопросы о раке груди на конференции ESMO 2025

荷爾蒙陽性乳癌怎麼治？CDK4/6標靶藥物、化療、荷爾蒙治療完整解析

DTACs Cyclin D1-CDK4/6 protein complex simulation.

PENELOPE-B: Exploration of CDK4/6 Inhibition in the Adjuvant Setting

Dr Bardia on T-DXd Efficacy By Pace of Prior CDK4/6 Inhibitor Progression in Breast Cancer

Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer

What is the role of CDK4/6 inhibitors in early breast cancer?

Dr Gandhi on Considerations for Continuing CDK4/6 Inhibitors After Progression in HR+ Breast Cancer

CDK 4/6 Inhibitors in Breast Cancer Advanced and Adjuvant Settings

Первый CDK4/6 ингибитор при раннем РМЖ

Metastatic HR+/HER2- Breast Cancer Case | CDK4/6 Inhibitors, CNS Progression & Treatment Strategies

FirstWord Analyst Notes Ibrance and the next generation of CDK4/6 inhibitors – KOLs speak out

"Optimizando los Resultados de los Anti CDK4/6 en el Tratamiento del Cáncer de Mama RH+ HER2-"

CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone recepto...

Event Topic: Evolving Landscape of CDK4/6i: Breast Cancer | Dr. Manish Singhal

When to Choose Chemotherapy vs CDK4/6 Inhibitors

Resistencia a CDK4/6i en cáncer de mama HR+: claves genómicas y terapias futuras

CDK4/6 inhibitors: Closing the express lane in breast cancer